1. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease
- Author
-
Britschgi, M., Olin, C.E., Johns, H.T., Takeda-Uchimura, Y., LeMieux, M.C., Rufibach, K., Rajadas, K., Zhang, H., Tomooka, B., Robinson, W.H., Clark, C.M., Fagan, A.M., Galasko, D.R., Holtzman, D.M., Jutel, M., Kaye, J.A., Lemere, C.A., Leszek, J., Li, G., Peskind, E.R., Quinn, J.F., Yesavage, J.A., Ghiso, J.A., and Wyss-Coray, T.
- Subjects
Alzheimer's disease -- Development and progression ,Antigen-antibody reactions -- Research ,Peptides -- Health aspects ,Aging -- Research ,Science and technology - Abstract
A number of distinct [beta]-amyloid (A[beta]) variants or multimers have been implicated in Alzheimer's disease (AD), and antibodies recognizing such peptides are in clinical trials. Humans have natural A[beta]-specific antibodies, but their diversity, abundance, and function in the general population remain largely unknown. Here, we demonstrate with peptide microarrays the presence of natural antibodies against known toxic A[beta] and amyloidogenic non-A[beta] species in plasma samples and cerebrospinal fluid of AD patients and healthy controls aged 21-89 years. Antibody reactivity was most prominent against oligomeric assemblies of A[beta] and pyroglutamate or oxidized residues, and IgGs specific for oligomeric preparations of A[beta]1-42 in particular declined with age and advancing AD. Most individuals showed unexpected antibody reactivities against peptides unique to autosomal dominant forms of dementia (mutant A[beta], ABri, ADan) and IgGs isolated from plasma of AD patients or healthy controls protected primary neurons from A[beta] toxicity. Aged vervets showed similar patterns of plasma IgG antibodies against amyloid peptides, and after immunization with A[beta] the monkeys developed high titers not only against A[beta] peptides but also against ABri and ADan peptides. Our findings support the concept of conformation-specific, cross-reactive antibodies that may protect against amyloidogenic toxic peptides. If a therapeutic benefit of A[beta] antibodies can be confirmed in AD patients, stimulating the production of such neuroprotective antibodies or passively administering them to the elderly population may provide a preventive measure toward AD.
- Published
- 2009